FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775241650> ?p ?o ?g. }

• W2775241650 endingPage "504" @default.
• W2775241650 startingPage "496" @default.
• W2775241650 abstract "PurposeThis study explored the validity of the First International Consensus on Mucous Membrane Pemphigoid (MMP) guidance, which recommends that clinically indistinguishable patients, who have direct immunofluorescence (DIF)-negative biopsies, be excluded from a diagnosis of MMP. Misdiagnosis, or delayed diagnosis, of MMP with ocular involvement leads to the inappropriate use of topical therapy, the standard of care for causes of cicatrising conjunctivitis other than MMP, rather than systemic immunomodulatory therapy, resulting in irreversible clinical deterioration in patients with MMP.DesignProspective, cross-sectional study.ParticipantsPatients meeting the clinical criteria of ocular MMP, including those with positive and negative DIF findings.MethodsA case report form was used to collect the demographic details, the clinical history, and the results of a detailed clinical assessment by ophthalmologists, otolaryngologists, dermatologists, and oral medicine specialists. All anatomic sites potentially affected by MMP were examined apart from the esophagus (and larynx in a subset). The DIF results were recorded.Main Outcome MeasuresDifferences between DIF-positive and -negative patients in demography, sites of involvement, and disease severity as determined by the degree of conjunctival scarring (using Tauber staging), central corneal disease (vascularization, scarring, ulceration, and conjunctivalization), history of conjunctival or lid surgery, and requirement for systemic immunotherapy at the time of screening.ResultsA total of 73 patients with ocular MMP were recruited, of whom 20 of 73 (27.4%) had ocular-only disease. There was no significant demographic or clinical difference between patients with positive and negative DIF results. This finding included differences in disease severity for which the only significant difference was that of more severe central corneal disease in DIF-negative patients. Asymptomatic disease at different sites was frequent.ConclusionsThese findings do not support the classification of DIF-negative patients, meeting the clinical criteria for ocular MMP, as having a different disease. This category of patients should be accepted as having DIF-negative MMP, for clinical management purposes, with patients having inflamed eyes being treated with systemic immunomodulatory therapy. The frequent finding of asymptomatic ocular, oral, and nasopharyngeal MMP is clinically significant and implies that these sites should be routinely screened in asymptomatic patients. This study explored the validity of the First International Consensus on Mucous Membrane Pemphigoid (MMP) guidance, which recommends that clinically indistinguishable patients, who have direct immunofluorescence (DIF)-negative biopsies, be excluded from a diagnosis of MMP. Misdiagnosis, or delayed diagnosis, of MMP with ocular involvement leads to the inappropriate use of topical therapy, the standard of care for causes of cicatrising conjunctivitis other than MMP, rather than systemic immunomodulatory therapy, resulting in irreversible clinical deterioration in patients with MMP. Prospective, cross-sectional study. Patients meeting the clinical criteria of ocular MMP, including those with positive and negative DIF findings. A case report form was used to collect the demographic details, the clinical history, and the results of a detailed clinical assessment by ophthalmologists, otolaryngologists, dermatologists, and oral medicine specialists. All anatomic sites potentially affected by MMP were examined apart from the esophagus (and larynx in a subset). The DIF results were recorded. Differences between DIF-positive and -negative patients in demography, sites of involvement, and disease severity as determined by the degree of conjunctival scarring (using Tauber staging), central corneal disease (vascularization, scarring, ulceration, and conjunctivalization), history of conjunctival or lid surgery, and requirement for systemic immunotherapy at the time of screening. A total of 73 patients with ocular MMP were recruited, of whom 20 of 73 (27.4%) had ocular-only disease. There was no significant demographic or clinical difference between patients with positive and negative DIF results. This finding included differences in disease severity for which the only significant difference was that of more severe central corneal disease in DIF-negative patients. Asymptomatic disease at different sites was frequent. These findings do not support the classification of DIF-negative patients, meeting the clinical criteria for ocular MMP, as having a different disease. This category of patients should be accepted as having DIF-negative MMP, for clinical management purposes, with patients having inflamed eyes being treated with systemic immunomodulatory therapy. The frequent finding of asymptomatic ocular, oral, and nasopharyngeal MMP is clinically significant and implies that these sites should be routinely screened in asymptomatic patients." @default.
• W2775241650 created "2017-12-22" @default.
• W2775241650 creator A5000992168 @default.
• W2775241650 creator A5004374998 @default.
• W2775241650 creator A5017040325 @default.
• W2775241650 creator A5019400717 @default.
• W2775241650 creator A5021917134 @default.
• W2775241650 creator A5025438582 @default.
• W2775241650 creator A5026141778 @default.
• W2775241650 creator A5029449398 @default.
• W2775241650 creator A5031211174 @default.
• W2775241650 creator A5032092414 @default.
• W2775241650 creator A5033290575 @default.
• W2775241650 creator A5039682959 @default.
• W2775241650 creator A5042046447 @default.
• W2775241650 creator A5043026550 @default.
• W2775241650 creator A5046331524 @default.
• W2775241650 creator A5049002575 @default.
• W2775241650 creator A5050863395 @default.
• W2775241650 creator A5054139143 @default.
• W2775241650 creator A5055915412 @default.
• W2775241650 creator A5058015714 @default.
• W2775241650 creator A5061034988 @default.
• W2775241650 creator A5069032977 @default.
• W2775241650 date "2018-04-01" @default.
• W2775241650 modified "2023-10-17" @default.
• W2775241650 title "Mucous Membrane Pemphigoid with Ocular Involvement" @default.
• W2775241650 cites W1586416377 @default.
• W2775241650 cites W1939054712 @default.
• W2775241650 cites W1972966166 @default.
• W2775241650 cites W1977712083 @default.
• W2775241650 cites W1984119250 @default.
• W2775241650 cites W1990092403 @default.
• W2775241650 cites W1992884814 @default.
• W2775241650 cites W2016697361 @default.
• W2775241650 cites W2024504427 @default.
• W2775241650 cites W2026442061 @default.
• W2775241650 cites W2027991725 @default.
• W2775241650 cites W2044603809 @default.
• W2775241650 cites W2045874942 @default.
• W2775241650 cites W2046402177 @default.
• W2775241650 cites W2048757622 @default.
• W2775241650 cites W2053849578 @default.
• W2775241650 cites W2072431780 @default.
• W2775241650 cites W2072881081 @default.
• W2775241650 cites W2075042833 @default.
• W2775241650 cites W2079966146 @default.
• W2775241650 cites W2098708745 @default.
• W2775241650 cites W2103294754 @default.
• W2775241650 cites W2118720612 @default.
• W2775241650 cites W2126254281 @default.
• W2775241650 cites W2133581180 @default.
• W2775241650 cites W2153763572 @default.
• W2775241650 cites W2340410882 @default.
• W2775241650 cites W2481199173 @default.
• W2775241650 cites W2497192058 @default.
• W2775241650 cites W2576426968 @default.
• W2775241650 cites W4211003831 @default.
• W2775241650 doi "https://doi.org/10.1016/j.ophtha.2017.10.004" @default.
• W2775241650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29217149" @default.
• W2775241650 hasPublicationYear "2018" @default.
• W2775241650 type Work @default.
• W2775241650 sameAs 2775241650 @default.
• W2775241650 citedByCount "49" @default.
• W2775241650 countsByYear W27752416502018 @default.
• W2775241650 countsByYear W27752416502019 @default.
• W2775241650 countsByYear W27752416502020 @default.
• W2775241650 countsByYear W27752416502021 @default.
• W2775241650 countsByYear W27752416502022 @default.
• W2775241650 countsByYear W27752416502023 @default.
• W2775241650 crossrefType "journal-article" @default.
• W2775241650 hasAuthorship W2775241650A5000992168 @default.
• W2775241650 hasAuthorship W2775241650A5004374998 @default.
• W2775241650 hasAuthorship W2775241650A5017040325 @default.
• W2775241650 hasAuthorship W2775241650A5019400717 @default.
• W2775241650 hasAuthorship W2775241650A5021917134 @default.
• W2775241650 hasAuthorship W2775241650A5025438582 @default.
• W2775241650 hasAuthorship W2775241650A5026141778 @default.
• W2775241650 hasAuthorship W2775241650A5029449398 @default.
• W2775241650 hasAuthorship W2775241650A5031211174 @default.
• W2775241650 hasAuthorship W2775241650A5032092414 @default.
• W2775241650 hasAuthorship W2775241650A5033290575 @default.
• W2775241650 hasAuthorship W2775241650A5039682959 @default.
• W2775241650 hasAuthorship W2775241650A5042046447 @default.
• W2775241650 hasAuthorship W2775241650A5043026550 @default.
• W2775241650 hasAuthorship W2775241650A5046331524 @default.
• W2775241650 hasAuthorship W2775241650A5049002575 @default.
• W2775241650 hasAuthorship W2775241650A5050863395 @default.
• W2775241650 hasAuthorship W2775241650A5054139143 @default.
• W2775241650 hasAuthorship W2775241650A5055915412 @default.
• W2775241650 hasAuthorship W2775241650A5058015714 @default.
• W2775241650 hasAuthorship W2775241650A5061034988 @default.
• W2775241650 hasAuthorship W2775241650A5069032977 @default.
• W2775241650 hasBestOaLocation W27752416501 @default.
• W2775241650 hasConcept C141071460 @default.
• W2775241650 hasConcept C142724271 @default.
• W2775241650 hasConcept C159654299 @default.
• W2775241650 hasConcept C16005928 @default.

• next